Abstract

Background: Since 2011, Taiwan’s National Health Insurance Administration (NHIA) issued a regulation on the reimbursement to anti-osteoporosis medications (AOMs). This study aimed to evaluate the impact of this regulation in reimbursement on the utilization of AOMs, clinical outcomes and associated medical expenditures of patients with incident hip fractures. Methods: By using the National Health Insurance Research Database (NHIRD), patients with incident hip fracture from 2006 to 2015 were identified as our study cohort. Patients younger than 50 years old or prescribed with AOMs within one year prior to incident fracture were excluded. Outcomes of interest were quarterly estimates of the proportion of patients who received bone mineral density (BMD) examination, who were prescribed AOMs, as well as who encountered subsequent osteoporotic fracture-related visits and associated medical expenditures. Particularly, age- and gender specific estimates were reported. An interrupted time series study design with segmented regression model was used to quantitatively explore the impact of the changes of the reimbursement criteria on the level (immediate) and trend (long-term) changes of these outcomes. Results: Our study enrolled 118 493 patients with incident hip fracture with those patients aged older than 80 years old accounting for the largest proportion. A significantly decreased trend of AOMs prescription rates was observed immediately post regulation except for female aged between 65 and 80, while the long-term pattern showed no significant difference. However, the percentage of patients encountered subsequent osteoporotic fracture-related visit was not statistically different between pre- and post-regulation periods. Noteworthy, the policy regulation was associated with an increasing trend of osteoporotic fracture associated medical expenditures, especially for patients older than 80 years old.Conclusion: The regulation on the reimbursement for AOMs decreased the prescribing rate of AOMs immediately although the effect did not sustain thereafter. However, higher subsequent osteoporotic fracture-related medical expenditures were introduced, especially among those very old population.

Highlights

  • In the United States, the direct economic burden of osteoporotic fractures was approximately $17 billion US dollars in 2005 and is projected to increase by 50% in 2025.4 There are approximately 536 000 new cases of fragility fractures in 2011 in the United Kingdom, and the economic burden due to new and prior fractures will increase by 24% to 6723 million euro in 2025.5 The estimated disability due to osteoporosis is greater than that caused by cancers and high blood pressure related heart disease.[6]

  • Well-documented evidences demonstrated that anti-osteoporosis medications (AOMs) can significantly

  • This study revealed that timely initiation of AOMs post hip fracture was important for patient and economic for National Health Insurance

Read more

Summary

Introduction

Osteoporosis and osteoporotic fractures are associated with increased morbidity and mortality as well as a decreased health-related quality of life.[1,2,3] In the United States, the direct economic burden of osteoporotic fractures was approximately $17 billion US dollars in 2005 and is projected to increase by 50% in 2025.4 There are approximately 536 000 new cases of fragility fractures in 2011 in the United Kingdom, and the economic burden due to new and prior fractures will increase by 24% to 6723 million euro in 2025.5 The estimated disability due to osteoporosis is greater than that caused by cancers (except for lung cancer) and high blood pressure related heart disease.[6]Osteoporosis incur significant clinical and economic burden in Taiwan. The results of Nutrition and Health Survey in Taiwan from 2002 to 2008 showed nearly one in two women and one in four men above 50 years old have a low bone mineral density (BMD) and is defined as osteoporosis.[7] According to our previous study using the National Health Insurance Research Database (NHIRD), there were nearly 337 000 diagnosed osteoporosis patients in 2013, and the incremental change of direct medical costs attributable to osteoporotic fractures were approximately 4000 US dollars per event.

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call